Erectile dysfunction (ED) is frequently associated with cardiovascular disease. Epidemiological data on the frequency of ED in vascular surgery patients is rarely reported. We evaluated the prevalence of this comorbidity in patients consulting the vascular surgery outpatient clinic. Over a 6-month period, a short version of the International Index of Erectile Function (IIEF) questionnaire consisting of six EDrelevant questions was handed out to 440 vascular surgery outpatients. Clinical data were collected from patients' records. Linear regression models with forward selection were used to investigate associations between erectile function score and possible risk factors. The return rate was 31% (137 patients). Eight patients (6%) were taking phosphodiesterase inhibitors. ED, as defined by an erectile function score of 25 or less and/or use of phosphodiesterase inhibitors, was found in 90% (95% CI: 84% to 95%) of cases. Moderate or severe ED, as defined by an erectile function score of 16 or less and/or use of phosphodiesterase inhibitors, was found in 70% (95% CI: 62% to 78%) of cases. Increased age, abdominal aortic aneurysm, peripheral arterial disease, urologic disease, insulin-dependent diabetes mellitus, and use of beta-blockers were significantly associated with a lower erectile function score. In conclusion, erectile dysfunction is a frequent and often missed comorbidity in vascular surgery patients. While ED may have a profound impact on the patient's quality of life, attention should also be paid to the patient's preoperative sexual function, considering the availability of oral pharmacotherapies and possible consequences concerning liability in postoperative patients in whom pre-existing ED was not identified properly.
Introduction
In recent years, there has been increasing awareness in the importance of cardiovascular comorbidities in patients presenting with erectile dysfunction (ED). Medical literature has reflected ongoing concerns over which cardiovascular patients are appropriate candidates for phosphodiesterase-5 (PDE-5) inhibitor therapies, but has not necessarily documented erectile function (EF) in patients presenting with advanced atherosclerotic diseases. [1] [2] [3] The prevalence of ED in patients with coronary heart disease has been investigated and occurs in approximately 39% of patients, increasing to approximately 56% in smoking cardiac patients. 4 ED also correlates significantly with the severity of coronary disease. 5 There is little epidemiological data concerning the prevalence of ED in vascular surgery patients. This is all the more important as frequently performed vascular surgery procedures may have an impact on EF: while aortoiliac revascularization and femoro-femoral bypass surgery have been shown to improve EF, 6, 7 interruption of the hypogastric nerve and/or occlusion of the hypogastric artery during open aortoiliac surgery may cause ED. 8 For these reasons, we decided to perform a clinical survey concerning EF in patients consulting our vascular surgery outpatient clinic.
Methods
We addressed the prevalence of ED among consecutive patients who consulted our clinic for a routine outpatient visit between December 2004 and May 2005. All male patients that were physically able to fill out the questionnaire were included. The questionnaire was handed out by a nurse after the patient registered and the patients were asked to return the form before leaving the clinic. All patients gave written informed consent and the study was approved by the institutional review board.
EF was evaluated by an abridged version of the International Index of Erectile Function (IIEF) questionnaire. 9 The original IIEF questionnaire consists of 15 questions, divided into five domains: erectile function, orgasmic function, sexual desire, intercourse satisfaction and overall satisfaction. 10 The six possible answers are graded from 0 to 5, reflecting grades from no intercourse to normal function. For our survey, the six questions focusing on EF were used (see Appendix). This 'Erectile Function Domain' of the IIEF has been validated by Cappelleri et al. 9 The total obtainable score for this subdomain is 30. Abnormal EF is defined as a score of 25 or less. 9 For the purpose of this study, the eight patients who were using PDE-5 inhibitors were considered to suffer from moderate to severe ED regardless of their actual EF score. Thus, we defined abnormal EF as a score of 25 or less, and/or use of PDE-5 inhibitors. However, existing data on the prevalence of ED often refer to moderate-to-severe disease, and this corresponds to an EF score of 16 or less. 9 Mild ED is defined as an EF score of 17-25. 9 The following patient information was collected: age, marital status, body mass index (BMI), systolic blood pressure, hypertension, smoking, diabetes, insulin-dependent diabetes (IDD), hyperlipidemia (HL), anti-hypertensive medications, statin use, alcohol use and use of PDE-5 inhibitors. Vascular morbidities including a history of carotid disease (CD), abdominal aortic aneurysm (AAA), peripheral artery disease (PAD) or coronary artery disease (CAD) were considered. CD was defined as a stenosis Ն60% on either duplex ultrasound or magnetic resonance imaging or a history of carotid endarterectomy. PAD was defined as an ankle-brachial index of less than 0.9 in patients with symptoms consistent with claudication. CAD was defined as angina pectoris or a history of coronary revascularization. All AAA patients had an aneurysm diameter of 40 mm or more and surgical status (pre-/postoperative) and type of treatment (open/endovascular) were recorded. A history of urological disease including benign prostatic hyperplasia, history of prostatic cancer or bladder cancer and urological pelvic surgery was also noted.
A small amount of clinical data was not available for certain patients.
Statistical analysis
Numerical variables were summarized with the sample median and range. The prevalence of abnormal EF was estimated with an exact 95% binomial confidence interval (CI). Linear regression models with forward selection were used to investigate associations between EF score and possible risk factors. Statistical significance was determined at the 5% level. No adjustments for multiple testing were made in these exploratory analyses. Owing to the fact that the EF score is likely influenced by the use of PDE-5 inhibitors on demand, we did not include the eight individuals taking these medications in the linear regression analysis.
Results
The questionnaire was handed out to 440 men. A total of 137 patients (31%) completed the form. For one patient no information regarding PDE-5 inhibitor use was available and one patient did not answer one of the ED questions. These two patients were excluded from the study. Eight patients were taking PDE-5 inhibitors on demand to treat moderate or severe ED. These eight patients had the following EF scores: 1, 2, 7, 11, 17, 22, 24, and 29. Demographic data of the included patients are given in Table 1 and associations between EF score and patient co-morbidities in patients not taking PDE-5 inhibitors on demand are given in Table 2 .
Abnormal EF was found in 122 out of 135 cases (90%, 95% CI: 84% to 95%). Moderate or severe disease was diagnosed in 95 patients (70%, 95% CI: 62% to 78%), with the remaining 27 patients (20%, 95% CI: 14% to 28%) diagnosed as mild ED. Median age was 69 years (range 36-85). The majority of patients returning questionnaires were married (84%). The most commonly reported cardiovascular risk factors were: hyperlipidemia, hypertension, and diabetes mellitus ( Table 1) . Some 57 patients (42%) had CAD, and moderate or severe ED was found in 77% of patients in this subgroup. A total of 45 patients (33%) had a history of CAD and the prevalence of moderate or severe ED was 60% in these men. Of the 32 patients with PAD, 88% suffered from moderate or severe ED. In patients with AAA, moderate or severe ED was reported by 40 out of 49 individuals (82%). Of the 49 patients with AAA, 28 (57%) had undergone a surgical intervention (n ϭ 8 for open repair, n ϭ 20 for endovascular repair). The ED score was not significantly associated with either operative status ( p ϭ 0.30), or whether open or endovascular techniques had been applied ( p ϭ 0.46).
Higher age was significantly associated with a lower EF score (p ϭ 0.007). Insulin-dependent diabetes ( p ϭ 0.003), urologic diseases ( p ϭ 0.004), PAD ( p Ͻ 0.001) and AAA ( p Ͻ 0.001) were other factors significantly associated with a lower EF score. Betablockers were the only medication that increased the EF score significantly ( p ϭ 0.006).
Discussion
The risk of deterioration of EF following surgical or interventional procedures, especially in the distal aortic and iliac regions, is well known. Although surgical techniques sparing the para-aortic and parailiac nerves have been described, [11] [12] [13] the risk of affecting normal EF has been reported to range between 8% and 83%. [14] [15] [16] Impairment of EF was also found as a consequence of hypogastric artery embolization (HAE) and occurred in 38% of cases after unilateral HAE and in 50% of cases after bilateral embolization. 17 Epidemiological data concerning the prevalence of ED in vascular surgery patients are sparse. In previous studies, a 23-40% prevalence of preoperative ED has been reported for patients with AAA (see Table 3 ). [14] [15] [16] [18] [19] [20] The frequency of ED in our population of AAA patients was two to three times higher.
The increasing prevalence of ED with advancing age is a well-known phenomenon. 21 However, compared with epidemiological studies based on the general population, ED was clearly more prevalent in the patients who responded to our survey, across all age groups (Table 4 ). [22] [23] [24] ED is frequently found in association with other cardiovascular risk factors including hypertension, hyperlipidemia, diabetes mellitus, smoking, obesity and a sedentary life style. [25] [26] [27] ED may complicate diabetes in 19-65% of cases 28, 29 and the risk is even higher for patients with diabetic neuropathy 28 and insulin dependency. 28, 30 We could only demonstrate a statistically significant association of insulin-dependent diabetes with poor EF. Other variables including hypertension, smoking and diabetes were negatively associated in this study, although results were not statistically significant. In the case of the risk factor smoking, it has been shown that the negative effect of this habit diminishes in older age groups 31 and in groups with multiple cardiovascular risk factors, 32 which may explain the lack of statistically significant association in our patients.
Certain medications influence EF. 33 While antihypertensives such as ACE inhibitors and angiotensin II antagonists have no negative effects on male sexual function, 34, 35 others, beta-blockers in particular, are known for their significant negative impact. 36 Indeed, it is estimated that up to 25% of erectile disabilities may be drug-induced. 21 In our patients, only betablockers had a negative association with the EF score that was statistically significant. In cases where a significant influence of beta-blockers on EF is suspected, a change of medication towards ACE inhibitors, ATII antagonists or cardiac-specific ␤1-blockers should be considered. 37 Differing methods of assessment and variable definitions of ED may also influence the reported The sample median and range are given for numerical variables. Moderate to severe ED was defined as an erectile function score of 16 or less and/or the use of PDE-5 inhibitors. Mild ED was defined as an erectile function score of 17-25. A small amount of data were not available for some of the demographics. The eight patients taking PDE-5 inhibitors were not included in these analyses. a For numerical variables, the estimated regression coefficient represents the change in the mean EF score corresponding to a one unit increase unless otherwise indicated in parenthesis. For categorical variables, the estimated regression coefficient represents the estimated mean EF score for those patients with the given characteristic minus the mean EF score for those without the characteristic. b p-Values result from linear regression models adjusted for age, abdominal aortic aneurysm, peripheral arterial disease, urologic disease, insulin-dependent diabetes, and beta-blocker use. Models involving diabetes were not adjusted for insulin-dependent diabetes, and models involving hypertension were not adjusted for beta-blocker use. Models involving surgery and type of surgery in abdominal aortic aneurysm patients were adjusted for age only.
prevalence. In previous studies, evaluation of EF was typically done by interview during clinic visits rather than by standardized and validated questionnaires. De Boer et al demonstrated that differences in questionnaires assessing EF have a considerable effect on the prevalence estimates of ED. 38 The IIEF is a validated questionnaire that seeks to identify and quantify the severity of ED; it was first used in the worldwide clinical trials of sildenafil citrate and has subsequently been used in both large-scale drug trials and clinical series. Since it quantifies small degrees of difference in erectile and male sexual function, using this questionnaire for clinical series may exaggerate the prevalence of ED. 38 Among the aforementioned surveys, only two used a modified version of the IIEF questionnaire. 15, 19 However, these were performed up to several years post-surgery and consequently a strong recall bias concerning the actual preoperative function may have influenced their results. Our study was one of the few to use a validated questionnaire, which may have added to the high prevalence of ED in our patients. The poor return rate of the questionnaire is certainly due to the delicate nature of the topic, and constitutes the major limitation of this investigation. However, our return rate is comparable with other studies investigating ED. 15, 19 It is possible that patients without ED are less likely to respond to the survey, which could at least in part explain the high prevalence of ED observed in this group of patients. In the hypothetical scenario that all 303 patients who did not respond to the survey did not have ED, the estimated prevalence of ED would be 27%, still a high prevalence though more consistent with findings in other studies.
Conclusions
Impaired EF can have a profound negative effect on the quality of life for both the patient and his partner. The vascular specialist should be aware of the high prevalence of ED in this patient population. Taking a history of vascular risk factors is one way of initiating enquiries about EF, thereby providing a means of overcoming barriers to discussion and treatment.
Attention to the preoperative status should also be paid, considering possible implications on liability. We strongly recommend the use of validated questionnaires in the preoperative assessment of EF. 24 427 10% 36% 57%
Present study 135 52% 67% 79%
